Advanced search
Publication Cover
OncoTargets and Therapy Volume 15, 2022 - Issue
Submit an article Journal homepage
139
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Successful Treatment with Short-Term Steroid Against Severe Hepatitis Confirmed by Liver Biopsy in a Patient with Advanced Squamous-Cell Lung Cancer Receiving a Combination of Pembrolizumab, Carboplatin, and Nab-Paclitaxel: A Case Report

Anna Hayashi1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, JapanCorrespondence[email protected]
,
Shinji Nakamichi1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, JapanORCID Iconhttps://orcid.org/0000-0002-2298-6945
ORCID Icon,
Yukako Nakayama1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, Japan
,
Atsuhiro Nagano1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, Japan
,
Erika Mikami1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, Japan
,
Natsuki Takano1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, JapanORCID Iconhttps://orcid.org/0000-0002-4367-7949
ORCID Icon,
Takehiro Tozuka1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, JapanORCID Iconhttps://orcid.org/0000-0002-3774-8915
ORCID Icon,
Masaru Matsumoto1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, Japan
,
Akihiko Miyanaga1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, JapanORCID Iconhttps://orcid.org/0000-0003-2026-9181
ORCID Icon,
Rintaro Noro1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, JapanORCID Iconhttps://orcid.org/0000-0003-4912-4138
ORCID Icon,
Yasuhiro Terasaki2 Department of Analytic Human Pathology, Nippon Medical School, Tokyo, Bunkyo-ku, JapanORCID Iconhttps://orcid.org/0000-0003-4495-7982
ORCID Icon,
Kaoru Kubota1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, Japan
,
Masahiro Seike1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, Japan
&
Akihiko Gemma1 Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Bunkyo-ku, Japan
 show all
Pages 637-642 | Published online: 07 Jun 2022

References

  • Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373(373):1627–1639. doi:10.1056/NEJMoa1507643
  • Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375(375):1823–1833. doi:10.1056/NEJMoa1606774
  • Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a Phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265. doi:10.1016/S0140-6736(16)32517-X
  • Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377(377):1919–1929. doi:10.1056/NEJMoa1709937
  • Gandhi L, Rodriguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. doi:10.1056/NEJMoa1801005
  • Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer. N Engl J Med. 2018;379:2040–2051. doi:10.1056/NEJMoa1810865
  • De Martin E, Michot JM, Papouin B, et al. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors. J Hepatol. 2018;68:1181–1190. doi:10.1016/j.jhep.2018.01.033
  • Nadeau B, Fecher L, Owens S, et al. Liver toxicity with cancer checkpoint inhibitor therapy. Semin Liver Dis. 2018;38:366–378. doi:10.1055/s-0038-1667358
  • Peeraphatdit T, Wang J, Odenwald MA, Hu S, Hart J, Charlton MR. Hepatotoxicity from immune checkpoint inhibitors: a systematic review and management recommendation. Hepatology. 2020;72(1):315–329. doi:10.1002/hep.31227
  • Mosedale M, Watkins PB. Drug-induced liver injury: advances in mechanistic understanding that will inform risk management. Clin Pharmacol Ther. 2017;101(4):469–480. doi:10.1002/cpt.564
  • Zen Y, Yeh MM. Hepatotoxicity of immune checkpoint inhibitors: a histology study of seven cases in comparison with autoimmune hepatitis and idiosyncratic drug-induced liver injury. Mod Pathol. 2018;31(6):965–973. doi:10.1038/s41379-018-0013-y
  • Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open. 2017;2(4):e000268. doi:10.1136/esmoopen-2017-000268
  • Kurokawa K, Hara M, Iwakami S, et al. Cholestatic injury induced by pembrolizumab in a patient with lung adenocarcinoma. Intern Med. 2019;58:3283–3287. doi:10.2169/internalmedicine.2591-18
  • Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:119–142. doi:10.1093/annonc/mdx225
  • Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018;36(36):1714–1768. doi:10.1200/JCO.2017.77.6385
  • Imoto K, Kohjima M, Hioki T, et al. Clinical features of liver injury induced by immune checkpoint inhibitors in Japanese patients. Can J Gastroenterol Hepatol. 2019;2019:6391712. doi:10.1155/2019/6391712

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.